Document is current
Any future updates will be listed below
-
Authors
Li, Shuya https://orcid.org/0000-0002-7263-0365
Pan, Yuesong https://orcid.org/0000-0003-3082-6789
Wang, Ziran
Liang, Zhigang
Chen, Huisheng https://orcid.org/0000-0002-8490-9435
Wang, Dong
Sui, Yi
Zhao, Xingquan
Wang, Yilong
Du, WanLiang https://orcid.org/0000-0002-9066-5078
Zheng, Huaguang https://orcid.org/0000-0001-6400-5474
Wang, Yongjun
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04676659 at ClinicalTrials.govnct03854500 at ClinicalTrials.govDocuments that mention this clinical trial
Safety and efficacy of tenecteplase versus alteplase in patients with acute ischaemic stroke (TRACE): a multicentre, randomised, open label, blinded-endpoint (PROBE) controlled phase II study
https://doi.org/10.1136/svn-2021-000978
nct02814409 at ClinicalTrials.govDocuments that mention this clinical trial
Safety and efficacy of tenecteplase versus alteplase in patients with acute ischaemic stroke (TRACE): a multicentre, randomised, open label, blinded-endpoint (PROBE) controlled phase II study
https://doi.org/10.1136/svn-2021-000978
nct03181360 at ClinicalTrials.govDocuments that mention this clinical trial
Safety and efficacy of tenecteplase versus alteplase in patients with acute ischaemic stroke (TRACE): a multicentre, randomised, open label, blinded-endpoint (PROBE) controlled phase II study
https://doi.org/10.1136/svn-2021-000978
European Stroke Organisation (ESO) - European Society for Minimally Invasive Neurological Therapy (ESMINT) Guidelines on Mechanical Thrombectomy in Acute Ischemic Stroke
https://doi.org/10.1136/neurintsurg-2018-014569
nct03889249 at ClinicalTrials.govDocuments that mention this clinical trial
Safety and efficacy of tenecteplase versus alteplase in patients with acute ischaemic stroke (TRACE): a multicentre, randomised, open label, blinded-endpoint (PROBE) controlled phase II study
https://doi.org/10.1136/svn-2021-000978
European Stroke Organisation (ESO) - European Society for Minimally Invasive Neurological Therapy (ESMINT) Guidelines on Mechanical Thrombectomy in Acute Ischemic Stroke
https://doi.org/10.1136/neurintsurg-2018-014569
European Stroke Organisation (ESO)–European Society for Minimally Invasive Neurological Therapy (ESMINT) expedited recommendation on indication for intravenous thrombolysis before mechanical thrombectomy in patients with acute ischemic stroke and anterior circulation large vessel occlusion
https://doi.org/10.1136/neurintsurg-2021-018589
Documents that mention this clinical trial
Intravenous tenecteplase compared with alteplase for minor ischaemic stroke: a secondary analysis of the AcT randomised clinical trial
https://doi.org/10.1136/svn-2023-002828
Effect of thrombolysis type on the efficacy of aspiration versus stent retriever first line thrombectomy: results from the AcT trial
https://doi.org/10.1136/jnis-2024-022268
Quality of Life After Intravenous Thrombolysis for Acute Ischemic Stroke: Results From the AcT Randomized Controlled Trial
https://doi.org/10.1161/strokeaha.123.044690
Safety and efficacy of tenecteplase versus alteplase in patients with acute ischaemic stroke (TRACE): a multicentre, randomised, open label, blinded-endpoint (PROBE) controlled phase II study
https://doi.org/10.1136/svn-2021-000978
Effect of Time to Thrombolysis on Clinical Outcomes in Patients With Acute Ischemic Stroke Treated With Tenecteplase Compared to Alteplase: Analysis From the AcT Randomized Controlled Trial
https://doi.org/10.1161/strokeaha.123.044267
Sex-Based Analysis of Workflow and Outcomes in Acute Ischemic Stroke Patients Treated With Alteplase Versus Tenecteplase
https://doi.org/10.1161/strokeaha.123.045320
Comparing Clinical Characteristics and Outcomes of Tenecteplase Versus Alteplase in Young Adult Patients With Stroke: A Secondary Analysis of the AcT Trial
https://doi.org/10.1161/svin.125.001974
Safety, Functional Disability, Healthcare Utilization, and Quality-of-Life Outcomes in Elderly Receiving Alteplase and Tenecteplase: A Secondary Analysis From the AcT Trial
https://doi.org/10.1161/strokeaha.124.049512
-
Funding
Funding for this research was provided by:
Guangzhou Recomgen Biotech Co.,Ltd.
the National Science and Technology Major Project (2017ZX09304018)
National Natural Science Foundation of China (81870905)
the National Key R&D Program of China (2017YFC1308204)
Beijing Municipal Administration of Hospitals Incubating Program (PX2018022)
- License Information
